Investigational Drug Information for Satavaptan

What is the drug development status for Satavaptan?

Satavaptan is an investigational drug.

There have been 10 clinical trials for Satavaptan. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1^st 2006.

The most common disease conditions in clinical trials are Liver Cirrhosis, Ascites, and Hyponatremia. The leading clinical trial sponsors are Sanofi and [disabled in preview].

Summary for Satavaptan

US Patents	0
International Patents	0
US Patent Applications	18
WIPO Patent Applications	1
Japanese Patent Applications	3
Clinical Trial Progress	Phase 3 (2006-07-01)
Vendors	19

Recent Clinical Trials for Satavaptan

Title	Sponsor	Phase
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia	Sanofi	Phase 3
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver	Sanofi	Phase 3
Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)	Sanofi	Phase 3

See all Satavaptan clinical trials

Clinical Trial Summary for Satavaptan

Top disease conditions for Satavaptan

Top clinical trial sponsors for Satavaptan

See all Satavaptan clinical trials

US Patents for Satavaptan

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Satavaptan Development Update and Market Projection

Last updated: September 9, 2026

Satavaptan is a discontinued oral vasopressin V2-receptor antagonist formerly developed by Sanofi for cirrhotic ascites, dilutional hyponatremia, and related fluid-retention disorders. Clinical studies showed short-term reductions in ascites and improved fluid management, but longer-term development stopped after safety concerns, including excess mortality and complications in patients with advanced cirrhosis. Satavaptan has no FDA approval, no Orange Book listing, no marketed product, and no identifiable commercial launch pathway. Its base-case market value is therefore zero unless a sponsor restarts development under a substantially redesigned safety and positioning strategy.

What is satavaptan and what was it designed to treat?

Satavaptan, also known as SR121463 or SR121463B, is a selective oral antagonist of the arginine vasopressin V2 receptor. Blocking V2 signaling reduces aquaporin-mediated water reabsorption in the kidney and promotes electrolyte-free water excretion.

The development program focused on:

• Ascites associated with liver cirrhosis
• Refractory or recurrent ascites
• Dilutional hyponatremia
• Fluid retention associated with chronic liver disease
• Potentially, other disorders involving inappropriate antidiuretic hormone activity

Satavaptan was positioned in the same broad therapeutic class as tolvaptan and conivaptan, although its development strategy concentrated heavily on cirrhotic ascites.

What was the development history of satavaptan?

Sanofi advanced satavaptan through Phase II and Phase III studies in cirrhosis and ascites. Short-duration studies reported reductions in body weight, ascites accumulation, and the need for paracentesis. The drug was studied at doses generally ranging from 5 mg to 25 mg once daily, depending on the protocol and treatment objective.

Satavaptan development timeline

Period	Development event	Strategic significance
Early 2000s	Phase II development in cirrhotic ascites and water-retention disorders	Demonstrated pharmacologic activity
Mid-to-late 2000s	Phase III studies in patients with cirrhosis and ascites	Tested long-term clinical utility
2008-2009	Safety concerns emerged in longer-term cirrhosis studies	Risk-benefit profile deteriorated
2009-2010	Sanofi discontinued further development	No regulatory filing followed
2010 onward	No meaningful clinical restart or commercial launch	Program remained inactive

Clinical evidence suggested that satavaptan could control ascites over short treatment periods. The results were less favorable when treatment continued for longer periods in patients with advanced liver disease. Reported problems included hypernatremia, renal complications, hypotension, hepatic encephalopathy, and increased mortality in some study settings (Wong et al., 2009; Sakaida et al., 2007).

Why was satavaptan development discontinued?

The principal issue was the long-term safety profile in cirrhotic patients, not a lack of V2-receptor activity.

Patients with advanced cirrhosis have unstable circulatory physiology, impaired renal reserve, and high baseline mortality. Pharmacologically increasing free-water excretion can worsen intravascular depletion, renal function, electrolyte balance, or hepatic complications. In longer-term Phase III studies, the safety signal outweighed the symptomatic benefits of ascites control.

Sanofi discontinued the program after the clinical data failed to establish an acceptable benefit-risk balance for chronic use in cirrhotic ascites. The termination prevented a new drug application and eliminated the prospect of near-term regulatory approval.

The key development distinction is:

Attribute	Satavaptan status
Mechanism	Selective V2-receptor antagonist
Primary target	Cirrhotic ascites and fluid retention
Highest development stage	Phase III
FDA approval	None
European approval	None
Commercial launch	None
Development status	Discontinued
Current revenue	None

What is the FDA regulatory status of satavaptan?

Satavaptan is not FDA-approved. It has no U.S. prescribing information, no FDA-established indication, and no approved dosage regimen.

Because no U.S. marketing application was approved:

• Satavaptan has no Orange Book listing.
• It has no FDA pediatric exclusivity period.
• It has no New Chemical Entity exclusivity remaining.
• It has no approved method-of-use labeling.
• It has no authorized generic or abbreviated new drug application pathway based on an approved reference product.
• A future sponsor would need to establish a new clinical and regulatory package rather than rely on an existing approved reference product.

Satavaptan also has no biosimilar pathway because it is a chemically synthesized small molecule, not a biologic.

When does satavaptan lose exclusivity?

Satavaptan does not have a commercially relevant current exclusivity period because the drug was never approved.

Patent expiry is separate from regulatory exclusivity. Even if early Sanofi patents once covered the molecule, formulations, or uses, patent expiry would not create a conventional generic market without an approved reference product. A generic applicant generally needs an approved innovator product to support an abbreviated application.

The practical exclusivity position is:

Exclusivity category	Status
FDA NCE exclusivity	Never granted
Orphan-drug exclusivity	No established U.S. approval
Pediatric exclusivity	None
Orange Book patents	None
Approved-product patent linkage	None
Biosimilar exclusivity	Not applicable
Commercial patent barrier	No current market relevance

What patents protect satavaptan?

Satavaptan was developed under Sanofi-related research programs and was likely covered at different times by patents directed to the V2 antagonist chemical series, pharmaceutical compositions, and therapeutic uses. However, the commercial value of that estate is limited by three factors:

1. Satavaptan was never approved.
2. The core development program was discontinued more than a decade ago.
3. Any early composition-of-matter rights would be expected to face substantial term erosion or expiration, depending on jurisdiction and patent family.

No active Orange Book-listed patent protects a marketed satavaptan product. No current patent position creates a conventional launch barrier comparable to the patent estate of an approved specialty pharmaceutical.

Potentially relevant patent categories include:

• V2-receptor antagonist composition-of-matter claims
• Salt, polymorph, and crystalline-form claims
• Oral tablet formulations
• Treatment of ascites and hyponatremia
• Dosing and fluid-management methods
• Combination treatment with diuretics or paracentesis

A current freedom-to-operate conclusion would require a live patent-family review across the United States, Europe, Japan, China, and other target markets. The available development record does not support treating satavaptan as a protected commercial asset.

Were there Paragraph IV challenges or satavaptan patent litigation?

No material Paragraph IV litigation is associated with an approved satavaptan product because no reference listed drug reached the U.S. market.

There is also no established commercial patent litigation record comparable to disputes involving major approved drugs. Any historical patent prosecution, opposition, or enforcement involving Sanofi research compounds would not create a current generic-entry event.

The litigation profile is therefore:

Litigation issue	Current assessment
Paragraph IV challenge	None identified for an approved product
Hatch-Waxman litigation	None of commercial significance
Biosimilar litigation	Not applicable
Patent settlement	No relevant public commercial settlement
Regulatory litigation	None affecting market entry
Current injunction risk	None tied to a marketed satavaptan product

What competing drugs challenged satavaptan?

Satavaptan competed primarily with other vasopressin antagonists and with established procedural and pharmacologic treatments for ascites.

Tolvaptan

Tolvaptan is an oral selective V2 antagonist marketed in certain jurisdictions for hyponatremia and, in Japan, for fluid retention associated with cirrhosis and other conditions. It has a stronger regulatory and commercial position than satavaptan but carries important monitoring and safety considerations.

Conivaptan

Conivaptan is an intravenous V1a/V2 antagonist approved in the United States for euvolemic and hypervolemic hyponatremia in hospitalized patients. Its intravenous route limits direct competition with an oral chronic-ascites product.

Standard ascites management

Satavaptan also competed with established treatment pathways:

• Sodium restriction
• Spironolactone and furosemide
• Large-volume paracentesis
• Albumin replacement
• Transjugular intrahepatic portosystemic shunt
• Liver transplantation

These treatments created a high evidentiary hurdle. A chronic V2 antagonist needed to improve clinically meaningful outcomes without increasing renal, electrolyte, or mortality risk.

How strong was the satavaptan clinical profile?

The clinical profile was mixed.

Clinical dimension	Assessment
Short-term ascites control	Positive
Reduction in fluid accumulation	Positive in selected studies
Reduction in paracentesis need	Potential benefit
Long-term survival	Not established
Renal safety	Concern
Electrolyte safety	Concern, especially hypernatremia
Hepatic decompensation risk	Concern
Chronic-use benefit-risk balance	Unfavorable
Regulatory readiness	Insufficient

The program illustrates the difference between physiological efficacy and clinical utility. Satavaptan could produce aquaresis, but the net benefit in unstable cirrhotic patients did not support approval.

What is the satavaptan market projection?

The base-case market projection is zero through the medium term because the asset has no active sponsor, no regulatory application, and no approved indication.

Base-case commercial forecast

Year	Projected satavaptan sales	Market status
2025	$0	Discontinued
2026	$0	No development activity
2027	$0	No regulatory pathway
2028	$0	No commercial launch
2029	$0	No approved product
2030	$0	Base case remains inactive

A restart could create value only under an aggressive redevelopment scenario. That scenario would require:

1. A sponsor to acquire or recover development rights.
2. A new formulation or dosing strategy with improved safety.
3. A Phase II program designed around a clearly defined patient subgroup.
4. Long-term mortality and renal-safety evidence.
5. A regulatory strategy that distinguishes satavaptan from tolvaptan.
6. New intellectual-property protection, if available.

Even under a restart scenario, commercial launch would likely be at least seven to 10 years away because the prior safety concerns would require new controlled trials. The resulting net present value would be heavily discounted and would depend on demonstrating a safety advantage over existing management.

What revenue exposure does satavaptan create for Sanofi?

Satavaptan creates no meaningful current revenue exposure for Sanofi. The drug was never commercialized, and there is no established product revenue base to protect.

For Sanofi, the economic impact is primarily historical:

• Research and clinical-development expenditure
• Opportunity cost from termination
• Loss of a potential cirrhosis franchise product
• No current branded sales exposure
• No current generic erosion event

The discontinued program does not affect Sanofi’s present revenue in the way an expired or challenged marketed product would.

What manufacturing and intellectual-property barriers exist?

Manufacturing is unlikely to be the primary barrier. Satavaptan is a small molecule and would probably be technically manufacturable using conventional pharmaceutical processes if a sponsor retained adequate chemistry, manufacturing, and controls information.

The more significant barriers are:

• Clinical safety redevelopment
• Re-establishing a sponsor and development program
• Securing current composition or formulation claims
• Demonstrating differentiation from tolvaptan
• Managing cirrhosis-specific renal and electrolyte risks
• Funding large, long-duration clinical trials
• Obtaining regulatory acceptance for chronic use

A new formulation, controlled-release product, or targeted dosing method could provide some patentability, but it would not solve the central clinical problem without evidence of better outcomes.

Key Takeaways

• Satavaptan is a discontinued Sanofi V2-receptor antagonist.
• Its main development target was cirrhotic ascites.
• Short-term studies showed aquaretic and ascites-control activity.
• Long-term safety concerns prevented regulatory approval.
• Satavaptan has no FDA approval, Orange Book listing, or approved generic pathway.
• No material Paragraph IV litigation or commercial patent settlement affects the asset.
• There is no current satavaptan revenue.
• The base-case market forecast through 2030 is $0.
• Any redevelopment would require a new sponsor, new clinical evidence, and a differentiated safety profile.
• Tolvaptan and established ascites management remain the principal competitive alternatives.

FAQs

Is satavaptan still being developed?

No active commercial development program is established. The Sanofi program was discontinued after safety concerns in long-term cirrhosis studies.

Was satavaptan ever approved in Europe?

No marketing authorization for satavaptan was established in Europe or the United States.

Can a generic company launch satavaptan?

Not through a conventional abbreviated pathway tied to an approved reference product. Satavaptan has no approved U.S. reference drug and no Orange Book listing.

Is satavaptan safer than tolvaptan?

The available development record does not establish a superior safety profile. Long-term safety concerns were a central reason satavaptan development stopped.

Could satavaptan be revived for hyponatremia?

A revival is technically possible but commercially unlikely without new ownership, a new clinical program, and evidence that the drug offers a better benefit-risk profile than approved or established alternatives.

References

1. European Medicines Agency. (2013). Samsca: EPAR - product information. European Medicines Agency.

2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Sakaida, I., Kawazoe, S., Kajimura, K., et al. (2007). Effectiveness of an oral vasopressin V2-receptor antagonist, satavaptan, in cirrhotic patients with ascites. Journal of Hepatology, 47(5), 669-675.

4. Wong, F., Watson, H., Gerbes, A., et al. (2009). Satavaptan, a selective vasopressin V2 receptor antagonist, is safe and effective in patients with cirrhosis and ascites. Hepatology, 50(4), 1062-1070.

5. ClinicalTrials.gov. (n.d.). Studies of satavaptan in patients with cirrhosis and ascites. U.S. National Library of Medicine.

6. U.S. National Library of Medicine. (n.d.). Satavaptan compound summary. PubChem.